In proceedings commenced by the Australian Competition and Consumer Commission, the Federal Court has found that Reckitt Benckiser (Australia) Pty Ltd (Reckitt Benckiser) engaged in misleading conduct in contravention of the Australian Consumer Law by representing that its Nurofen Specific Pain products were each formulated to treat a specific type of pain, when the products are identical.
The Nurofen Specific Pain product range consists of Nurofen Back Pain, Nurofen Period Pain, Nurofen Migraine Pain and Nurofen Tension Headache.
The court found that Reckitt Benckiser made misleading representations on the packaging of each Nurofen Specific Pain product, and on its website http://www.nurofen.com.au(link is external), that each product:
•was formulated to treat a particular type of pain; and
•solely or specifically treated a particular type of pain.
In fact, each product contains the same active ingredient, ibuprofen lysine 342mg, and is no more effective at treating the type of pain described on its packaging than any of the other Nurofen Specific Pain products.
Reckitt Benckiser admitted that it had engaged in the contravening conduct and consented to the orders made by the Court.
Could we say that this was just a harmless marketing ploy, or did they treat us consumers with contempt?
